Currently, the stock price of Protagonist Therapeutics Inc. (PTGX) is $18.00. In the most recent trading session, the stock underwent a significant upswing, peaking at $18.66 after opening at $18.51. The stock touched a low of $17.86 before closing at $18.44.
Protagonist Therapeutics Inc.’s stock market performance has been consistent. The 1-year high for the company’s stock was recorded at $30.10 on 06/12/23, with the lowest value being $7.24 on 11/28/22.
Top 5 EV Tech Stocks to Buy for 2023
The electric vehicle boom is accelerating – and fast. According a new report published by BloombergNEF, annual spending on passenger EVs hit $388 billion in 2022, up 53% from the year before. Like we said, the boom is accelerating – and the time to buy EV-related tech stocks is now. Get our free report, "Top 5 EV Tech Stocks to Buy for 2023".
Click Here to Download the FREE Report.
Sponsored
52-week price history of PTGX Stock
A stock’s 52-week high and low prices can reveal a great deal about its present condition and potential future performance. Protagonist Therapeutics Inc.’s current trading price is -40.20% away from its 52-week high, while its distance from the 52-week low is 148.79%. The stock’s price range during this period has fluctuated between $7.24 and $30.10. Shares of the company, which operates in the Healthcare sector, recorded a trading volume of around 0.59 million for the day, which was evidently lower than the average daily volume of 0.99 million over the last three months.
Financial Performance and Market Capitalization
Protagonist Therapeutics Inc. (PTGX) has experienced a quarterly decline of -37.33% in its revenues when compared to the same period in the previous year. Presently, the company has a total market capitalization of 1.02B and boasts a workforce of 106 employees.
Analysts’ Ratings For Protagonist Therapeutics Inc.
As of right now, 5 analysts are rating Protagonist Therapeutics Inc. as a BUY, 0 of the polled analysts branded the stock as an OVERWEIGHT, 0 analyst is recommending to HOLD this stock, 0 of them gave the stock UNDERWEIGHT rating, and 0 analyst is rating the stock as SELL.
Moving average and trading volume data
Based on Barchart.com data, the company’s moving average over the 100-day period was 22.95, with a change in price of -6.02. Similarly, Protagonist Therapeutics Inc. recorded 954,697 in trading volume during the last 100 days, posting a change of -25.06%.
PTGX Debt-to-equity ratio analysis
The debt-to-equity (D/E) ratio is a valuable metric that offers insight into a company’s financial health and standing in the market. This ratio is calculated by dividing a company’s current total liabilities by its shareholders’ equity. The D/E ratio illustrates the extent of debt a company is utilizing to support its assets in relation to the value of its shareholders’ equity. At the time of writing, the total D/E ratio for PTGX stands at 0.00. Similarly, the long-term debt-to-equity ratio is also 0.00.
PTGX Stock Stochastic Average
The raw stochastic average for Protagonist Therapeutics Inc. over the last 50 days is presently at 3.00%. This reflects a drop from the raw stochastic average of the previous 20 days, which was noted at 5.15%. Further, the company’s Stochastic %K and %D values for the last 20 days were 16.04% and 24.49%, respectively.
PTGX Stock Price Performance Analysis
Investors have been left with mixed emotions regarding the stock price performance over the year, as it’s been a mixed bag. This year’s metric has recorded a Price increase of 64.99%. However, over the past six months, we’ve seen a stronger performance of -25.16%. The price of PTGX leaped by -4.05% over the last 30 days. And in the last five days, it has fallen by -4.05%.
